
107 patients were evaluated for eligibility
22 patients excluded (did not meet eligibility criteria)
85 patients enrolled and randomly assigned
42 patients assigned to the experimental arm
• 41 patients received the assigned treatment
• 12 patients did not start carboplatin-gemcitabine
• 1 patient did not received any assigned treatment
43 patients assigned to the control arm
• 43 patients received the assigned treatment
Reasons for treatment discontinuation
• 18 patients due to disease progression (42.9%)
• 8 patients due to clinical progression (19%)
• 6 patients due to adverse events (14.3%)
• 5 patients due to physician decision (11.9%)
• 1 patient due to consent withdrawal (2.4%)
Reasons for treatment discontinuation
• 6 patients due to disease progression (14%)
• 3 patients due to adverse events (7%)
• 2 patients due to physician decision (4.6%)
• 2 patients due to consent withdrawal (4.6%)
• 1 patient due to clinical progression (2.3%)